카드리틱스, Inc.
US ˙ NasdaqGM ˙ US14161W1053

SecurityCDLX / Cardlytics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership227,731 shares
Latest Disclosed Value $ 239,118
State Street Corp ownership in CDLX / Cardlytics, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 227,731 shares of Cardlytics, Inc. (US:CDLX) valued at $239,118 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 227,731 shares of Cardlytics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $138,939 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CARDLYTICS COM 14161W105 227,731 0 0.00 239 -8.43 0.0000
2026-02-13 2025-12-31 13F CARDLYTICS COM 14161W105 227,731 0 0.00 262 -52.80 0.0000
2025-11-14 2025-09-30 13F CARDLYTICS COM 14161W105 227,731 -3,000 -1.30 553 45.91 0.0000
2025-08-14 2025-06-30 13F CARDLYTICS COM 14161W105 230,731 -669,905 -74.38 380 -76.88 0.0000
2025-05-15 2025-03-31 13F CARDLYTICS COM 14161W105 900,636 -9,630 -1.06 1,639 -51.47 0.0001
2025-02-14 2024-12-31 13F CARDLYTICS COM 14161W105 910,266 36,934 4.23 3,377 20.87 0.0001
2024-11-14 2024-09-30 13F CARDLYTICS COM 14161W105 873,332 -17,558 -1.97 2,795 -61.80 0.0001
2024-08-14 2024-06-30 13F CARDLYTICS COM 14161W105 890,890 141,674 18.91 7,314 -32.63 0.0003
2024-05-15 2024-03-31 13F CARDLYTICS COM 14161W105 749,216 30,357 4.22 10,856 63.99 0.0005
2024-02-14 2023-12-31 13F CARDLYTICS COM 14161W105 718,859 39,847 5.87 6,621 -40.91 0.0003
2023-11-14 2023-09-30 13F CARDLYTICS COM 14161W105 679,012 15,641 2.36 11,204 167.25 0.0006
2023-08-14 2023-06-30 13F CARDLYTICS COM 14161W105 663,371 64,816 10.83 4,193 106.30 0.0002
2023-05-15 2023-03-31 13F CARDLYTICS COM 14161W105 598,555 -66,610 -10.01 2,032 -47.14 0.0001
2023-05-15 2022-12-31 13F/A-99 CARDLYTICS COM 14161W105 665,165 -3,087 -0.46 3,845 -38.81 0.0002
2023-05-15 2022-12-31 13F CARDLYTICS COM 14161W105 665,165 -3,087 3,845 0.0002
2022-11-15 2022-09-30 13F CARDLYTICS COM 14161W105 668,252 5,801 0.88 6,282 -57.49 0.0004
2022-08-15 2022-06-30 13F CARDLYTICS COM 14161W105 662,451 14,372 2.22 14,779 -58.52 0.0009
2022-05-16 2022-03-31 13F CARDLYTICS COM 14161W105 648,079 20,973 3.34 35,631 -14.03 0.0018
2022-02-14 2021-12-31 13F CARDLYTICS COM 14161W105 627,106 11,367 1.85 41,445 -19.81 0.0020
2021-11-15 2021-09-30 13F CARDLYTICS COM 14161W105 615,739 12,817 2.13 51,685 -32.46 0.0027
2021-08-16 2021-06-30 13F CARDLYTICS COM 14161W105 602,922 44,277 7.93 76,529 24.88 0.0040
2021-07-09 2021-03-31 13F/A-1 CARDLYTICS COM 14161W105 558,645 48,272 9.46 61,283 -15.90 0.0035
2021-05-17 2021-03-31 13F CARDLYTICS COM 14161W105 558,645 48,272 61,283 0.0035
2021-02-16 2020-12-31 13F CARDLYTICS COM 14161W105 510,373 12,419 2.49 72,866 107.35 0.0045
2020-11-10 2020-09-30 13F CARDLYTICS COM 14161W105 497,954 -16,839 -3.27 35,141 -2.45 0.0024
2020-08-14 2020-06-30 13F CARDLYTICS COM 14161W105 514,793 197,870 62.43 36,025 225.14 0.0026
2020-06-19 2020-03-31 13F/A-1 CARDLYTICS COM 14161W105 316,923 15,996 5.32 11,080 -41.43 0.0010
2020-05-11 2020-03-31 13F CARDLYTICS COM 14161W105 316,923 15,996 11,080 973.0471
2020-02-06 2019-12-31 13F CARDLYTICS COM 14161W105 300,927 53,982 21.86 18,916 128.51 0.0013
2019-11-14 2019-09-30 13F CARDLYTICS COM 14161W105 246,945 11,812 5.02 8,278 35.50 0.0006
2019-08-14 2019-06-30 13F CARDLYTICS COM 14161W105 235,133 156,838 200.32 6,109 371.74 0.0005
2019-05-15 2019-03-31 13F CARDLYTICS COM 14161W105 78,295 3,939 5.30 1,295 60.87 0.0001
2019-02-12 2018-12-31 13F CARDLYTICS COM 14161W105 74,356 -7,035 -8.64 805 -60.56 0.0001
2018-11-09 2018-09-30 13F CARDLYTICS Common Stock 14161W105 81,391 3,600 4.63 2,041 20.63 0.0002
2018-08-14 2018-06-30 13F CARDLYTICS Common Stock 14161W105 77,791 17,091 28.16 1,692 90.54 0.0001
2018-05-15 2018-03-31 13F CARDLYTICS Common Stock 14161W105 60,700 60,700 888 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.